98446-55-0

Usage

Uses

Used in Pharmaceutical Industry:
5-Acetamido-2-chloroanisole is used as a building block for the synthesis of various pharmaceuticals due to its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Acetamido-2-chloroanisole is employed as a precursor in the production of agrochemicals, aiding in the creation of compounds that can protect crops from pests and diseases.
Used as an Antifungal Agent:
5-Acetamido-2-chloroanisole is used for its potential antifungal properties, being studied for applications in controlling fungal infections in various settings, including medical and agricultural uses.
Used in Chemical Research:
As a valuable intermediate, 5-Acetamido-2-chloroanisole is used in chemical research to explore its reactivity and potential to form new compounds, contributing to the advancement of chemical science and technology.

InChI:InChI=1/C9H10ClNO2/c1-6(12)11-7-3-4-8(10)9(5-7)13-2/h3-5H,1-2H3,(H,11,12)

Upstream product

• 57046-02-3 acetic acid-(2,4-dichloro-5-methyl-anilide) 
• 588-16-9 m-methoxyacetanilide 
• 108-24-7 acetic anhydride 
• 13726-14-2 4-chloro-m-anisidine 

Downstream Products

• 1374606-57-1 N-(4-chloro-5-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide 
• 62492-43-7 acetic acid-(4-chloro-5-methoxy-2-methyl-anilide) 

Relevant academic research and scientific papers

Discovery and optimization of quinolinone derivatives as potent, selective, and orally bioavailable mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors

Mutations at the arginine residue (R132) in isocitrate dehydrogenase 1 (IDH1) are frequently identified in various human cancers. Inhibition of mutant IDH1 (mIDH1) with small molecules has been clinically validated as a promising therapeutic treatment for acute myeloid leukemia and multiple solid tumors. Herein, we report the discovery and optimization of a series of quinolinones to provide potent and orally bioavailable mIDH1 inhibitors with selectivity over wild-type IDH1. The X-ray structure of an early lead 24 in complex with mIDH1-R132H shows that the inhibitor unexpectedly binds to an allosteric site. Efforts to improve the in vitro and in vivo absorption, distribution, metabolism, and excretion (ADME) properties of 24 yielded a preclinical candidate 63. The detailed preclinical ADME and pharmacology studies of 63 support further development of quinolinone-based mIDH1 inhibitors as therapeutic agents in human trials.

PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R8 are described herein.

FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula (I) where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.

QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where Y1, X1, X2, Y

Herbicidal 1-aryl-4-substituted-1,4-dihydro-5H-tetrazol-5-ones and sulfur analogs thereof

Herbicidal aryltetrazolinones and thiones of the formula STR1 in which W is oxygen or sulfur; R is alkyl, fluoroalkyl, alkenyl, haloalkenyl, cyanoalkyl, alkylthioalkyl, haloalkoxyalkyl, trifluoromethylthio or alkoxyalkyl; one of X1 and X2 is fluorine, chlorine, or bromine and the other is fluorine, chlorine, bromine, alkyl, nitro or haloalkyl; and Z is a group selected from a variety of substituents including 2-propynyloxy as disclosed and exemplified.